The main limitation of this study lies in its non-randomized design, precluding direct comparisons with immunotherapy and other BRAF / MEK inhibitors currently approved for the treatment of patients with metastatic melanoma. This evidence concerns the gene MAP2K7 and metastatic melanoma.